About clinuvel pharmaceuticals ltd - CLVLY
Clinuvel Pharmaceuticals Ltd. operates as a biopharmaceutical company. The firm engages in the development of SCENESSE, its proprietary photoprotective drug. It also offers drugs for the treatment of various skin disorders. The company was founded by Robert Thomas Dorr on December 14, 1999 and is headquartered in Melbourne, Australia.
CLVLY At a Glance
Clinuvel Pharmaceuticals Ltd.
535 Bourke Street
Melbourne, Victoria (VIC) 3000
| Phone | 61-3-9660-4900 | Revenue | 61.54M | |
| Industry | Pharmaceuticals: Major | Net Income | 23.43M | |
| Sector | Health Technology | 2025 Sales Growth | 6.497% | |
| Fiscal Year-end | 06 / 2026 | Employees | N/A | |
| View SEC Filings |
CLVLY Valuation
| P/E Current | 17.933 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 14.543 |
| Price to Sales Ratio | 5.57 |
| Price to Book Ratio | 2.161 |
| Price to Cash Flow Ratio | 12.88 |
| Enterprise Value to EBITDA | 7.13 |
| Enterprise Value to Sales | 3.189 |
| Total Debt to Enterprise Value | 0.002 |
CLVLY Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | N/A |
| Receivables Turnover | 3.419 |
| Total Asset Turnover | 0.369 |
CLVLY Liquidity
| Current Ratio | 9.664 |
| Quick Ratio | 9.34 |
| Cash Ratio | 8.236 |
CLVLY Profitability
| Gross Margin | 65.78 |
| Operating Margin | 43.476 |
| Pretax Margin | 54.256 |
| Net Margin | 38.069 |
| Return on Assets | 14.043 |
| Return on Equity | 15.969 |
| Return on Total Capital | 14.812 |
| Return on Invested Capital | 15.947 |
CLVLY Capital Structure
| Total Debt to Total Equity | 0.219 |
| Total Debt to Total Capital | 0.219 |
| Total Debt to Total Assets | 0.194 |
| Long-Term Debt to Equity | 0.04 |
| Long-Term Debt to Total Capital | 0.04 |